Similar articles

• Reply: Statin Intolerance and Risk for Recurrent Myocardial Infarction, Coronary Heart Disease Events, and All-Cause Mortality.

  Serban MC, Muntner P, Rosenson RS. Serban MC, et al. J Am Coll Cardiol. 2017 Aug 1;70(5):685-686. doi: 10.1016/j.jacc.2017.04.066. J Am Coll Cardiol. 2017. PMID: 28750708 No abstract available.
• Statin Intolerance and the Obsession With Aggressive Cholesterol Lowering to Prevent Coronary Heart Disease.

  Mascitelli L, Goldstein MR. Mascitelli L, et al. J Am Coll Cardiol. 2017 Aug 1;70(5):684. doi: 10.1016/j.jacc.2017.04.065. J Am Coll Cardiol. 2017. PMID: 28750707 No abstract available.
• Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction: A Cohort Study.

  Booth JN 3rd, Colantonio LD, Chen L, Rosenson RS, Monda KL, Safford MM, Kilgore ML, Brown TM, Taylor B, Dent R, Muntner P, Levitan EB. Booth JN 3rd, et al. Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10):e003626. doi: 10.1161/CIRCOUTCOMES.117.003626. Circ Cardiovasc Qual Outcomes. 2017. PMID: 29021332
• Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy.

  Kinjo K, Sato H, Sakata Y, Nakatani D, Mizuno H, Shimizu M, Nishino M, Ito H, Tanouchi J, Nanto S, Hori M; Osaka Acute Coronary Insufficiency Study (OACIS) Group. Kinjo K, et al. Am J Cardiol. 2005 Sep 1;96(5):617-21. doi: 10.1016/j.amjcard.2005.04.030. Am J Cardiol. 2005. PMID: 16125481 Review.
• Statin intolerance - a question of definition.

  Algharably EA, Filler I, Rosenfeld S, Grabowski K, Kreutz R. Algharably EA, et al. Expert Opin Drug Saf. 2017 Jan;16(1):55-63. doi: 10.1080/14740338.2017.1238898. Epub 2016 Sep 27. Expert Opin Drug Saf. 2017. PMID: 27645111 Review.